plantar fascitis. plantar fascitis
Conditions
Interventions
Intervention 1: Control Group : A 2.5 ml syringe is filled with 1 ml steroid solution injection contained 40mg/ml methylprednisolone and 1 ml of 2% lidocaine. Intervention 2: prolotherapy Group: A 2.5
Treatment - Other
Control Group : A 2.5 ml syringe is filled with 1 ml steroid solution injection contained 40mg/ml methylprednisolone and 1 ml of 2% lidocaine.
prolotherapy Group: A 2.5 ml syringe is filled with 1 ml of 2% lidocaine (20 mg/ ml) and 1 ml of 50% dextrose (25 g/50 ml) (dextrose monohydrate 500 mg) giving a 25% dextrose solution. Injection is pe
Sponsors
Shiraz University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age 18-70 years old, clinical diagnosis of plantar fasciitis in the past 6 months, Diagnosis of plantar fasciitis was on the basis of pain at, or around, the plantar surface of the heel or the medial longitudinal arch, Exclusion criteria: chronic plantar fasciitis with systemic symptoms, evidence of pathologic disorders in laboratory data or radiograph of foot, steroid or prolotherapy drug solution injection in 3 months prior to the study, severe co-existing disease such as diabetes, inflammatory arthritis or previous foot surgery
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain intensity. Timepoint: befor intervention; 2 and 6 weeks after intervention. Method of measurement: Visual Analogue ScaLe(VAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: second and sixth weeks. Method of measurement: examination, side effects such as rupture of ligament, heel pad atrophy, hypopigmentation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mostafa Jazayeri Shoshtari
Shiraz University of Medical Sciences and Health Services
Outcome results
None listed